EcoDrugPlus

Matrix Metallopeptidase 9

Ensembl ID : ENSMAMG00000010804
Gene Symbol: MMP9
3 Cross references
215 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSMAMG00000013377
Gene Symbol: MTOR
2 Cross references
216 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSMAMG00000020664
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSMAMG00000012735
Gene Symbol: MC4R
3 Cross references
89 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSMAMG00000020588
Gene Symbol: LOC113121716
2 Cross references
214 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSMAMG00000009883
Gene Symbol: MTNR1AA
3 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSMAMG00000013324
Gene Symbol: MME
4 Cross references
231 Possible Orthologues:

Metabotropic Glutamate Receptor 4-Like

Ensembl ID : ENSMAMG00000003997
Gene Symbol: LOC113130969
2 Cross references
207 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSMAMG00000016805
Gene Symbol: METAP2
4 Cross references
220 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSMAMG00000007921
Gene Symbol: LOC113135593
2 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSMAMG00000015823
Gene Symbol: MAPK1
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSMAMG00000015614
Gene Symbol: MAPK10
3 Cross references
88 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).